These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 10860896)

  • 1. Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection.
    Gerber JG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S123-9. PubMed ID: 10860896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological considerations in antiretroviral therapy.
    Sommadossi JP
    Antivir Ther; 1998; 3 Suppl 4():9-12. PubMed ID: 10723503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapies.
    Owen WF
    Clin Podiatr Med Surg; 1998 Apr; 15(2):227-39. PubMed ID: 9576051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical issues regarding the use of antiretroviral therapy for HIV infection.
    Deeks SG
    West J Med; 1998 Feb; 168(2):133-9. PubMed ID: 9499754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute pancreatitis associated with different combination therapies in patients infected with human immunodeficiency virus.
    Guo JJ; Jang R; Louder A; Cluxton RJ
    Pharmacotherapy; 2005 Aug; 25(8):1044-54. PubMed ID: 16207094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State of the art: antiretroviral and prophylactic treatments in HIV/AIDS.
    Porche DJ
    Nurs Clin North Am; 1999 Mar; 34(1):95-112. PubMed ID: 9922281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
    Joly V; Yeni P
    Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
    Joly V; Descamps D; Yeni P
    AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular factors for resistance against antiretroviral agents.
    Fridland A; Connelly MC; Robbins BL
    Antivir Ther; 2000 Sep; 5(3):181-5. PubMed ID: 11075937
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
    Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
    J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New antiretroviral drugs, part II: NRTIs, NNRTIs, and beyond.
    Murphy RL
    AIDS Clin Care; 1999 Jun; 11(6):47-9, 51, 53-4. PubMed ID: 11366882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 protease inhibitors.
    Eron JJ
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S160-70. PubMed ID: 10860901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of HIV infection.
    Chang YC; Tyring SK
    Dermatol Ther; 2004; 17(6):449-64. PubMed ID: 15571495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.
    Bozzette SA; Ake CF; Tam HK; Chang SW; Louis TA
    N Engl J Med; 2003 Feb; 348(8):702-10. PubMed ID: 12594314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
    Wilkins E
    J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
    [No Abstract]   [Full Text] [Related]  

  • 19. Elevated plasma concentrations of protease inhibitors and nonnucleoside reverse transcriptase inhibitors in patients coinfected with human immunodeficiency virus and hepatitis B or C: case series and literature review.
    Robertson SM; Scarsi KK; Postelnick MJ; Lynch P
    Pharmacotherapy; 2005 Aug; 25(8):1068-72. PubMed ID: 16207097
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capravirine, a nonnucleoside reverse-transcriptase inhibitor in patients infected with HIV-1: a phase 1 study.
    Gewurz BE; Jacobs M; Proper JA; Dahl TA; Fujiwara T; Dezube BJ
    J Infect Dis; 2004 Dec; 190(11):1957-61. PubMed ID: 15529260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.